Clinical Trial

Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma

Not Yet Recruiting Phase 2

Summary

This is a phase 2, multicentre, open-label, randomised, controlled trial with a parallel-group design. The study aims to evaluate the efficacy and safety of single-agent Becotatug Vedotin as adjuvant therapy in patients with high-risk locoregionally advanced nasopharyngeal carcinoma (NPC).

Protocol Amendment History 4 changes

critical Primary endpoint(s) modified 2026-06-10

notable Enrollment reduced: 218 -> 140 participants 2026-06-10

notable Primary completion pushed: 2030-04-15 -> 2030-08-31 2026-06-10

minor Completion pushed: 2033-04-15 -> 2033-08-31 2026-06-10

Trial Details

NCT Number	NCT07303283
Lead Sponsor	Kai Hu Collaborators: Wuzhou Red Cross Hospital, First People's Hospital of Yulin, Guigang People's Hospital, Hainan Cancer Hospital, Afﬁliated Hospital of North Sichuan Medical College, Lingshan people's Hospital, LiuZhou People's Hospital, The Third people's hospital of Hechi, the second People's Hospital of qinzhou, Hunan Cancer Hospital, Fujian Cancer Hospital, Guangxi Nanxishan Hospital, Liuzhou Workers' Hospital, Affiliated Hospital of Youjiang Medical University for Nationalitie
Conditions	Nasopharyngeal Carcinoma (NPC), Locoregionally Advanced Nasopharyngeal Carcinoma, Adjuvant Therapy
Enrollment	140 participants
Start Date	2026-09-01
Primary Completion	2030-08-31 (estimated)
Study Completion	2033-08-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-09